Latest Breaking News On - மருந்து ஹோல்டிங்ஸ் வரையறுக்கப்பட்டவை - Page 1 : comparemela.com

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Lee’s Pharmaceutical Announces its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento . Sorrento Therapeutics, Inc.March 8, 2021 GMT Socazolimab is an anti-PD-L1 antibody licensed from Sorrento for the Greater China Territory by Lee’s Pharm. China’s National Medical Products Administration (“NMPA”) clears Lee’s Pharm to conduct a Phase III, multicenter, randomized, double blinded, parallel-group clinical trial of Socazolimab (anti-PD-L1 monoclonal antibody, formerly known as ZKAB001) combined with chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer. SAN DIEGO, March 07, 2021 (GLOBE NEWSWIRE) China Oncology Focus Limited (COF), an affiliate of Lee’s Pharmaceutical Holdings Limited (Lee’s Pharm, HKEX: 950) announced that its anti-PD-L1 antibody, Socazolimab, licensed from Sorrento to COF for the greater China territory, has been cle

United statesHong kongRepublic of chinaTaiwan generalAlexis nahamaHenry jiLee pharmVivian fungSemnur pharmaceuticals incZhaoke ophthalmologyExchange commissionChina oncology focusSorrento therapeutics incChina national medical products administrationChina oncology focus limitedCorporate development